IL3RA and Hodgkins lymphoma: Ruella et al. reported that immunosuppressive M2-type TAM expressed high levels of CD123 in Hodgkin lymphoma TME, and anti-CD123 chimeric antigen receptor (CAR) T cells could recognize and kill TAMs thereby overcoming immunosuppression, representing a promising new therapeutic approach (Ruella et al., 2017).